Nomi Health vs Tempus AI
A detailed comparison to help you choose between Nomi Health and Tempus AI.
🏆
Verdict: Tempus AI wins
Tempus AI scores 4.1/5, edging out Nomi Health at 3.5/5. Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access.
Nomi Health AI-powered virtual care for chronic disease management | Tempus AI AI for precision medicine and clinical genomics | |
|---|---|---|
| Rating | 3.5 (1 review) | 4.1 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $1000/mo | From $1000/mo |
| Best For | Self-funded mid-market and large employers with workforces concentrated in Nomi's network markets (Michigan, Texas, Georgia, Ohio, Florida) who want direct provider contracts, claims-level analytics and a measurable savings methodology. | Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | team features | ssoteam features |
| Visit Nomi Health → | Visit Tempus AI → |
Nomi Health
Pros
- + Artemis analytics segments spend by condition, site of care and vendor against the employer's own claims; micro-segmentation produced an actionable 40-person cohort in my walkthrough within a few clicks
- + Savings measured against PPO-equivalent cost on volume actually steered to Network providers — trackable in claims data rather than projected, which is the methodology a CFO can audit
- + Network design removes member cost-sharing entirely ($0 copays, no deductibles) at direct-contracted health systems
- + Payments infrastructure pays providers in days rather than months, reducing rate-shock pricing built into provider contracts
- + Vendor publishes outcome data (Michigan year-one: 30% average savings, 16% fewer ER visits) and puts its direct-contracting thesis in front of Congress rather than only in sales decks
Cons
- - Network coverage is roughly two dozen US markets concentrated in the Midwest and South; national employers get partial coverage at best
- - No published pricing of any kind — the catalog's $1,000 minimum is unsupported by any source I could find
- - Implementation is a benefits-infrastructure project involving TPA, broker and finance; not self-serve
- - The 9% increase in outpatient surgeries in the same vendor data suggests utilization shifting rather than uniformly falling — savings claims need cohort-level scrutiny
- - Payments business (serving TPAs and providers) may shift incentives away from pure plan-savings alignment over time
Tempus AI
Pros
- + FY2025 revenue of $1.3B with 126% net revenue retention and >$1.1B remaining contract value — verifiable public-company financials, not marketing claims
- + Complete assay portfolio in one relationship: xT/xR comprehensive profiling, xF+ liquid biopsy, MRD monitoring, Ambry hereditary testing and OneOme pharmacogenomics (national launch July 2026)
- + Tempus One answered voice queries against the patient's own clinical and molecular profile in my testing, with report citations instead of generic text
- + Paige Predict extends the platform into digital pathology — 123 biomarkers predicted from standard H&E slides across 16 cancer types (vendor-published validation)
- + Trial matching is built into the report workflow, which is the practical bottleneck for oncology coordinators
Cons
- - No self-serve access, no trial, and no published pricing of any kind — the $1,000 entry figure floating around listings could not be verified
- - Oncology-first scope; primary care and non-oncology specialties have little reason to engage
- - Still net-loss-making (-$245.0M in 2025), and the portfolio is stitched from four recent acquisitions (Ambry, Paige, OneOme, Deep 6)
- - Model-performance and data-library claims are company-published; independent third-party validation is thinner than the press-release volume suggests
- - Enterprise sales motion means long procurement cycles for health systems
Frequently Asked Questions
Which is better, Nomi Health or Tempus AI?▼
Tempus AI scores higher at 4.1/5 vs 3.5/5 for Nomi Health, making it the better-rated option in our comparison.
What is the difference between Nomi Health and Tempus AI?▼
Nomi Health: Nomi Health is a payments and analytics platform for self-funded employer healthcare, handling direct provider contracts and claims payments. Tempus AI: Tempus AI runs clinical and genomic sequencing and builds the diagnostics and data products used in precision oncology and other specialties.
Is Nomi Health or Tempus AI more affordable?▼
Nomi Health starts at €1000/mo, Tempus AI starts at €1000/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.